Tag

Acoramidis

All articles tagged with #acoramidis

biotechhealthcare2 years ago•0 min saved

BridgeBio Secures $250M PIPE Financing Led by Qatar Investment Authority

Biotech company BridgeBio is set to receive approximately $250 million through a private investment in public equity (PIPE) as it approaches the submission for approval of its heart pill, acoramidis. This comes two months after the company announced positive Phase III results, which caused its shares to surge by 50%. The PIPE will bring in new long-term shareholders and addresses the question of BridgeBio's financial strategy following its recent success.

via Endpoints News|

#acoramidis #approval-submission #biotechhealthcare

health2 years ago•1 min saved

BridgeBio's Heart Disease Drug Achieves Late-Stage Study Goal, Sparking Soaring Share Prices

BridgeBio Pharma's experimental drug, acoramidis, has shown significant improvement in patients with transthyretin amyloid cardiomyopathy, a rare heart disease, according to a late-stage study. The drug demonstrated a 1.8 times better outcome than placebo in preventing death, hospitalization, and improving walking distance. It also improved survival by 81% compared to the placebo and reduced heart disease-related hospitalizations by 50%. No safety concerns were identified. BridgeBio plans to submit the data to the FDA by the end of 2023 for marketing approval.

via Reuters|

#acoramidis #bridgebio-pharma #fda

health2 years ago•1 min saved

BridgeBio Pharma's Heart Disease Drug Succeeds in Late-Stage Study

BridgeBio Pharma's experimental drug, acoramidis, has shown statistically significant improvement in reducing hospitalizations in a late-stage study for a rare heart disease that can lead to heart failure. The company plans to submit marketing applications to the US FDA by the end of 2023 and pursue regulatory filings in additional markets in 2024. Shares of BridgeBio Pharma surged 64% following the positive results.

via Yahoo Finance|

#acoramidis #bridgebio-pharma #health

healthcare2 years ago•0 min saved

BridgeBio's ATTR-CM Trial Demonstrates Significant Mortality and Hospitalization Reduction

BridgeBio has announced positive results from its Phase III trial of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The trial showed improvements in mortality, cardiovascular-related hospitalizations, a six-minute walk test, and a biomarker of the disease. Patients receiving the drug had an 81% survival rate at 30 months, compared to 74% on placebo, and the drug reduced hospitalization rates by 50%.

via Endpoints News|

#acoramidis #attr-cm #bridgebio